Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:52:34时区推断·⟳ 抓取 20:53:55·⚡ 决策 08-04 22:03:59 +1h10m·83.9 天前
强生任命Tom Cavanaugh自2026年9月1日起接任创新药业务负责人
强生宣布Jennifer Taubert退休，Tom Cavanaugh将于2026年9月1日起接任创新药业务负责人。
📄 原文Investing.com↗ 原文
Johnson & Johnson names Tom Cavanaugh to lead innovative medicine
BofA says this memory stock could double. Here are 5 reasons why NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE:JNJ) ann…
不做 Johnson & Johnson（JNJ.US）
超大市值公司常规高管交接，不构成短周期可量化交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 报道强生创新药业务负责人继任安排，生效日为2026年9月1日。
关键理由
- 强生宣布Jennifer Taubert退休，Tom Cavanaugh将于2026年9月1日起接任创新药业务负责人。
- 创新药业务年收入超过600亿美元，但本次只是管理层交接安排。
主要风险
- 强生为超大市值公司，常规高管任命不改变短期收入、利润或监管边界。
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 1,684 字
BofA says this memory stock could double. Here are 5 reasons why
NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE:JNJ) announced today that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine after more than 21 years with the company.
Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed Taubert effective September 1, 2026. He will join the Johnson & Johnson Executive Committee on that date, according to a press release statement.
Under Taubert’s leadership, the company’s Innovative Medicine business grew to more than $60 billion in annual revenue. She joined Johnson & Johnson and held various positions including roles in global commercial strategy, acquisitions, and therapeutic area development before becoming Worldwide Chairman.
Cavanaugh joined Johnson & Johnson in 2017 and has held senior leadership positions in Oncology, Immunology and Global Commercial Strategy. Most recently, he led the company’s North America region. Prior to Johnson & Johnson, he spent nearly 15 years at Celgene in product development, medical affairs, marketing, and regional management roles in Spain and the United States.
"I am pleased to appoint Tom to this important role as we advance our pipeline and bring transformative medicines to patients around the world," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson.
The transition is scheduled to occur over the coming weeks to ensure continuity in the Innovative Medicine business operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE:JNJ) announced today that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine after more than 21 years with the company.
Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed Taubert effective September 1, 2026. He will join the Johnson & Johnson Executive Committee on that date, according to a press release statement.
Under Taubert’s leadership, the company’s Innovative Medicine business grew to more than $60 billion in annual revenue. She joined Johnson & Johnson and held various positions including roles in global commercial strategy, acquisitions, and therapeutic area development before becoming Worldwide Chairman.
Cavanaugh joined Johnson & Johnson in 2017 and has held senior leadership positions in Oncology, Immunology and Global Commercial Strategy. Most recently, he led the company’s North America region. Prior to Johnson & Johnson, he spent nearly 15 years at Celgene in product development, medical affairs, marketing, and regional management roles in Spain and the United States.
"I am pleased to appoint Tom to this important role as we advance our pipeline and bring transformative medicines to patients around the world," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson.
The transition is scheduled to occur over the coming weeks to ensure continuity in the Innovative Medicine business operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。